US Injectable Drug Delivery Market worth $465.15 billion by 2031
The report "US Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) - Forecast to 2031" projected to reach USD 465.15 billion by 2031 from USD 309.90 billion in 2026, at a CAGR of 8.5% during the forecast period.
Browse 200 market data Tables and 65 Figures spread through 250 Pages and in-depth TOC on "US Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/us-injectable-drug-delivery-market-151115401.html
The US injectable drug delivery market is experiencing strong growth driven by demographic, clinical, and technological trends. Rising demand for effective, patient-friendly therapies and precision treatment options is accelerating the adoption of advanced injectables, including biologics, long-acting drugs, and self-administration systems. Pharmaceutical and biotech companies are increasingly collaborating with device developers and CDMOs to enhance product performance, ensure manufacturing scalability, and shorten commercialization timelines. Technological advancements, such as AI-assisted formulation design, smart injector platforms, automation in fill-finish operations, and advanced combination product engineering, are transforming delivery models and enabling more accurate and personalized dosing. In addition, the growing use of connected health tools, continuous manufacturing technologies, and robust quality management platforms is improving efficiency, traceability, and market responsiveness across the injectable delivery ecosystem in the US.
By product, the formulations segment accounted for the largest market share in 2025.
In the US injectable drug delivery market, the formulations segment accounted for the largest market share in 2025. This dominance is primarily because injectable therapies rely heavily on stability, solubility, and bioavailability optimization, making formulation development central to product success. The rise of biologics, long-acting injectables, and complex molecules requires sophisticated formulation science to ensure efficacy and patient safety. Additionally, continuous innovation in sustained-release systems, preservative-free formulations, and combination products drives significant investment, reinforcing formulations as the dominant segment in the market.
By therapeutic application, autoimmune diseases accounted for the largest share of the market in 2025.
In 2025, autoimmune diseases accounted for the largest share of the US injectable drug delivery market. This is because they rely heavily on injectable biologics and targeted therapies, which often provide faster and more effective symptom control than oral treatments. The rising prevalence of conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease continues to drive strong demand for long-term injectable regimens. Additionally, continuous innovation in monoclonal antibodies and self-injectable delivery systems further accelerates adoption, solidifying this segment’s leading position in the market.
Key Market Players
The prominent players in the US injectable drug delivery market are BD (US), West Pharmaceutical Services, Inc. (US), Cardinal Health (US), Baxter (US), B. Braun SE (Germany), Pfizer Inc. (US), Johnson & Johnson (US), Merck & Co., Inc. (US), Eli Lilly and Company (US), AbbVie Inc. (US), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the US Injectable Drug Delivery Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
